Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
- Status
- RECRUITING
- Phase
- PHASE2
Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
- Status
- RECRUITING
- Phase
- PHASE2
Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
- Status
- WITHDRAWN
- Phase
- PHASE2
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
- Status
- RECRUITING
- Phase
- PHASE2
Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC
- Status
- RECRUITING
- Phase
- PHASE2
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)
- Status
- RECRUITING
- Phase
- PHASE2